Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.

Biological chemistry - 26 Sept 2017

Maseko Sibusiso B, Padayachee Eden, Govender Thavendran, Sayed Yasien, Kruger Gert, Maguire Glenn E M, Lin Johnson

Abstract excerpt

The efficacy of HIV-1 protease (PR) inhibition therapies is often compromised by the emergence of mutations in the PR molecule that reduces the binding affinity of inhibitors while maintaining viable catalytic activity and affinity for natural substrates. In the present study, we used a recombinant HIV-1 C-SA PR and a recently reported variant for inhibition (Ki, IC50) and thermodynamic studies against nine...

Topics

Join the communities discussing this publication.

Biocatalysis
Drug Resistance, Viral
HIV-1
HIV Protease
HIV Protease Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Models, Molecular

Source

Identifiers

PMID: 28525359
DOI: 10.1515/hsz-2017-0107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.PMID 28525359Read ↗

Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic StudySemantic proximity Read ↗

The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.Semantic proximity Read ↗

Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistanceSemantic proximity Read ↗

Non-active site mutations in the HIV protease: Diminished drug binding affinity is achieved through modulating the hydrophobic sliding mechanism.Semantic proximity Read ↗

Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.Semantic proximity Read ↗

Evaluating the potency of HIV-1 protease drugs to combat resistance.Semantic proximity Read ↗

Impact of M36I polymorphism on the interaction of HIV-1 protease with its substrates: insights from molecular dynamicsSemantic proximity Read ↗

HIV-1 Vif protein sequence variations in South African people living with HIV and their influence on Vif-APOBEC3G interactionSemantic proximity Read ↗

Binding kinetics of highly mutated HIV-1 subtype C protease inhibition by Lopinavir and Darunavir in the face of altered conformational dynamics.Semantic proximity Read ↗

Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.Semantic proximity Read ↗

F99 is critical for dimerization and activation of South African HIV-1 subtype C protease.Semantic proximity Read ↗

Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.